These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11303846)

  • 1. Cefepime microbiologic profile and update.
    Kessler RE
    Pediatr Infect Dis J; 2001 Mar; 20(3):331-6. PubMed ID: 11303846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
    Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
    Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro study of antibacterial activity of cefepime (Axepim) against gram negative bacteria: comparison with cephalosporins and other beta-lactams].
    Vachée A; Devalckenaere A; Husson MO; Izard D
    Pathol Biol (Paris); 1996 Feb; 44(2):132-7. PubMed ID: 8761598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cefepime (maxipime), large spectrum 4th generation cephalosporin, resistant to beta-lactamases].
    Angelescu M; Apostol A
    Chirurgia (Bucur); 2001; 96(6):547-52. PubMed ID: 12731231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of cefepime against nosocomial isolates.
    Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
    J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of cefepime and other antimicrobials: survey of European isolates.
    Thornsberry C; Brown SD; Yee YC; Bouchillon SK; Marler JK; Rich T
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():31-53. PubMed ID: 8150766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
    Lim VK; Halijah MY
    Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
    Chong Y; Lee K; Kwon OH
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():21-9. PubMed ID: 8150765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime: a fourth-generation parenteral cephalosporin.
    Wynd MA; Paladino JA
    Ann Pharmacother; 1996 Dec; 30(12):1414-24. PubMed ID: 8968455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
    Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
    J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.